Predictive Oncology Files 8-K with Financials

TL;DR

Predictive Oncology (POAI) filed an 8-K on Dec 2nd, reporting on Dec 1st events. Includes financials.

AI Summary

Predictive Oncology Inc. filed an 8-K on December 2, 2025, reporting on events as of December 1, 2025. The filing includes financial statements and exhibits, with "Other Events" as a key item. The company, formerly known as Skyline Medical Inc., is incorporated in Delaware and headquartered in Pittsburgh, PA.

Why It Matters

This 8-K filing provides updated information and financial details for Predictive Oncology Inc., which is crucial for investors to assess the company's current status and performance.

Risk Assessment

Risk Level: low — This filing is a routine 8-K reporting on events and financial statements, not indicating any immediate material adverse changes.

Key Players & Entities

• Predictive Oncology Inc. (company) — Registrant
• Skyline Medical Inc. (company) — Former company name
• December 1, 2025 (date) — Date of earliest event reported
• December 2, 2025 (date) — Filing date
• Pittsburgh, PA (location) — Company headquarters

FAQ

Key Financial Figures

• $0.01 — nge on which registered Common stock, $0.01 par value POAI NASDAQ Capital Market

Filing Documents

• f8k_120225.htm (8-K) — 23KB
• exh_991.htm (EX-99.1) — 9KB
• 0001171843-25-007724.txt ( ) — 198KB
• poai-20251202.xsd (EX-101.SCH) — 3KB
• poai-20251202_lab.xml (EX-101.LAB) — 33KB
• poai-20251202_pre.xml (EX-101.PRE) — 22KB
• f8k_120225_htm.xml (XML) — 4KB

01 Other Events

Item 8.01 Other Events. On December 1, 2025, Predictive Oncology Inc. (the "Company") received formal notice from the Nasdaq Hearings Panel (the "Panel") of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it was in compliance with the stockholders' equity requirement set forth in Nasdaq Listing Rule 5550(b)(1) (the "Stockholders' Equity Requirement"). Accordingly, the previously disclosed listing matter has been closed. Nasdaq's notice further stated that pursuant to Listing Rule 5815(d)(4)(B), the Company will be subject to a mandatory panel monitor for a period of one year from December 1, 2025. If, within that one-year monitoring period, the Nasdaq Listing Qualification Staff (the "Staff") finds the Company again out of compliance with the Stockholders' Equity Requirement, notwithstanding Rule 5810(c)(2), the Company will not be permitted to provide the Staff with a plan of compliance with respect to that deficiency and Staff will not be permitted to grant additional time for the Company to regain compliance with respect to that deficiency, nor will the Company be afforded an applicable cure or compliance period pursuant to Nasdaq Listing Rule 5810(c)(3). Instead, the Staff will issue a delist determination letter and the Company will have an opportunity to request a new hearing with the initial Panel or a newly convened hearings panel if the initial Panel is unavailable. On December 2, 2025, the Company issued a press release announcing that it had regained compliance with the Stockholders' Equity Requirement. A copy of the press release is filed herewith as Exhibit 99.1 and is incorporated herein by reference.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release of Predictive Oncology, dated December 2, 2025 104 Cover Page Interactive Data File (embedded within the inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Predictive Oncology Inc. Date: December 2, 2025 By: /s/ Josh Blacher Josh Blacher Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR